Fig. 5: BMF expression correlates with response to antimitotic drug chemotherapy.

a BMF, FOXM1, and BUB1B transcript levels in MCF-7 and MDA-MB-231 cells. b BMF, FOXM1, and BUB1B transcript levels in asynchronous (untreated, unt) and mitotic (shake-off upon STLC) MDA-MB-231 cells depleted with Neg or FOXM1 siRNAs. c Individual cell fate profiling of siNeg- (n = 150) or siFOXM1-depleted (n = 150) MCF-7 cells treated with 500 nM TX. MD mitotic duration. d Cell fate percentage of the experiments described in c. e Individual cell fate profiling of siNeg- (n = 150) or siFOXM1-depleted (n = 150) MDA-MB-231 cells treated with 500 nM TX. MD, mitotic duration. f Cell fate percentage of the experiments described in e. g Correlation of BMF mRNA levels and paclitaxel drug sensitivity in the CTRP drug response data set. h Correlation of BMF protein levels and paclitaxel drug sensitivity in the CTRP drug response data set. i Relative BMF mRNA expression levels in tumors with complete/near-complete response vs. no response to a combination of docetaxel and capecitabine⁴⁰. j Correlation of BUB1B mRNA levels and paclitaxel drug sensitivity in the CTRP drug response data set. k Correlation of BUB1B protein levels and paclitaxel drug sensitivity in the CTRP drug response data set. l Relative BUB1B mRNA expression levels in tumors with complete/near-complete response vs. no response to a combination of docetaxel and capecitabine⁴⁰. Data information: In a data are mean ± S.D. from n = 3 independent experiments; *p ≤ 0.05 (two-tailed paired t test). In b data are mean ± S.D. from n = 3 independent experiments; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 (two-tailed one-way ANOVA and Tukey’s multiple comparison test). In d, f data are mean ± S.D. of n = 3 independent experiments; *p ≤ 0.05, ****p ≤ 0.0001 (two-tailed χ²). In g, h, j, k **p ≤ 0.01, **** p ≤ 0.0001 (https://depmap.org/portal/interactive/). In i, l ***p ≤ 0.001, ns p > 0.05 (two-tailed Mann–Whitney test).